| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/30/2006 | US7053228 Cushing disease; antidepressant; modulate immunology response |
| 05/30/2006 | US7053219 such as 5-methyl-6-(4-methoxyphenyl)-3-pyridin-4-yl-isoxazolo[4,5-c]pyridin-4(5H)one which has metabotropic glutamic acid receptor-antagonistic effect; for treatment of anxiety disorders, psychosomatic disorders, and eating disorders |
| 05/30/2006 | US7053215 For therapy of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes |
| 05/30/2006 | US7053183 Human cyclic nucleotide-gated cation channel polypeptide |
| 05/30/2006 | US7053116 Contacting cells with phenyl benzopyranone compound or or enantiomers, diastereomeric isomers or mixtures of any two or more thereof, or pharmaceutically acceptable salts thereof for blocking amyloid toxicity in cells |
| 05/30/2006 | US7053113 Mannich base prodrugs of 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives |
| 05/30/2006 | US7053109 Aminediols for the treatment of Alzheimer's disease |
| 05/30/2006 | US7053108 Indoline compounds |
| 05/30/2006 | US7053103 A pyrazolo[3,4-B]pyridine derivatives; corticotropin releasing factor receptor antagonists; treating stress-related illnesses, mood disorders, eating disorders, stress-induced gastrointestinal dysfunctions, neurodegenerative diseases, and neuropsychiatric disorders |
| 05/30/2006 | US7053101 Orphan opioid receptor (orl-1) ligands; anxiety, depression, neuropathic and acute pain, migraines, asthma, improved cognition |
| 05/30/2006 | US7053099 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors |
| 05/30/2006 | US7053098 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors |
| 05/30/2006 | US7053097 Inhibitors of glycogen synthase 3 kinase |
| 05/30/2006 | US7053093 Nitrogen compounds such as 1-((3- Phenylimidazo(5,1-a)-isoquinolin-6-yl)carbonyl)piperidine, that bind preferentially to gamma-aminobutyric acid (GABAA) receptors; prophylaxis of nervous system disorders |
| 05/30/2006 | US7053089 Such as 4-((methyl-pyrimidin-2-ylamino)-methyl)-piperidine-1-carboxylic acid benzyl ester; useful for pain relief; treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, and stroke; N-methyl-D-aspartate (NMDA) |
| 05/30/2006 | US7053088 Vanilloid receptor ligands and their use in treatments |
| 05/30/2006 | US7053087 Aminocycloalkyl cinnamide compounds for arrhythmia and analgesics and anesthetics |
| 05/30/2006 | US7053086 For cancer therapy |
| 05/30/2006 | US7053084 Antagonist for preventing the deposits of amyloid protein, for treating neurodegenerative disease, Alzheimer's disease and Down's Syndrome; (2R,3S) N1-[1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide |
| 05/30/2006 | US7053082 Neuroprotectants for treating epilepsy, stroke, Parkinson's disease, multiple sclerosis or amyotropic lateral sclerosis; 5-(3-methyl-4-amino or nitro-phenyl)-1,3-dioxolo[4,5-h][2,3]benzodiazepine; AMPA/cainate antagonistic effect; chemical intermediates |
| 05/30/2006 | US7053081 Cyclic malonamides as inhibitors of A-β protein production |
| 05/30/2006 | US7053057 Caspase inhibitors and uses thereof |
| 05/30/2006 | US7053056 Antiinflammatory agents; autoimmune disease; antiischemic agents |
| 05/30/2006 | US7053055 Compounds of unstable DP IV-inhibitors |
| 05/30/2006 | US7053053 for diagnostic/therapeutic/prophylactics for neurodegenerative diseases, brain dysfunctions, cancers, gastrointestinal/circulatory/endocrine diseases and cell death; genetic engineering |
| 05/30/2006 | US7052913 capsules comprising biocompatible silica sol-gel matrices that encapsulate chemical intermediates or prodrugs that convert when contacted with tissues and/or fluids; grafting encapsulated L-amino acid decarboxylase in the brain to convert L-dopa to dopamine for prophylaxis of Parkinson's disease |
| 05/30/2006 | US7052906 Synthetic transmembrane components |
| 05/30/2006 | US7052896 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| 05/30/2006 | US7052702 comprises a light-chain or a heavy-chain fragment of a Pseudonomas neurotoxin with a proteolytically active enzyme domain; N-acetylgalactosamine-binding lectins; to inhibit the release of neurotransmitters from neurons thereby reducing and/or preventing transmission of afferent pain signals |
| 05/30/2006 | US7052687 Human recombinant beta-interferon with improved solubility |
| 05/30/2006 | US7052684 Methods of healing wounds and fibrotic disorders using IL-10 |
| 05/30/2006 | US7052680 aerosols containing antiparkinsons drugs benzotropine, pergolide, amantadine, deprenyl and ropinerole, that have been heated on a solid support such as foil and condensed by passing through a flow of air |
| 05/30/2006 | US7052679 thin film of drugs; heating; dispensing as aerosol condensation |
| 05/30/2006 | CA2375908C Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 05/30/2006 | CA2354605C Diazabicyclooctane derivatives and therapeutic uses thereof |
| 05/30/2006 | CA2345582C Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol |
| 05/30/2006 | CA2321380C 6-azauracil derivatives as thyroid receptor ligands |
| 05/30/2006 | CA2263663C Substituted gamma aminobutyric acids as pharmaceutical agents |
| 05/30/2006 | CA2195243C Triazole compounds and the use thereof |
| 05/30/2006 | CA2157668C Tricyclic 2,3,4,5-tetrahydro-1h-3-benzazepines, their use and preparation |
| 05/26/2006 | WO2006055964A2 Zolmitriptan crystal forms |
| 05/26/2006 | WO2006055747A2 Bis(thio-hydrazide amides) for increasing hsp70 expression |
| 05/26/2006 | WO2006055711A1 Compositions containing aloe vera isolate and a prebiotic and their therapeutic application |
| 05/26/2006 | WO2006054938A1 Gaba-steroid antagonists and their use for the treatment of cns disorders |
| 05/26/2006 | WO2006054912A1 Aryl(hetaryl)-3-aminomethyl-quinilone-2 derivatives in the form of no-synthetase i and cyclooxygenase-2 nhibitors, methods for the production thereof and compositions based thereon |
| 05/26/2006 | WO2006054757A1 Caspase inhibitor |
| 05/26/2006 | WO2006054691A1 Soluble protein and utilization of the same |
| 05/26/2006 | WO2006054652A1 Amide compound |
| 05/26/2006 | WO2006054641A1 Gpr7-selective ligand and use thereof |
| 05/26/2006 | WO2006054600A1 Novel protein and preventive/remedy for neurodegenerative disease such as polyglutamine disease using the same |
| 05/26/2006 | WO2006054514A1 Preventive or therapeutic pharmaceutical composition for neuropathic pain |
| 05/26/2006 | WO2006054298A2 Glycogen synthase kinase-3 inhibitors |
| 05/26/2006 | WO2006053899A1 Cabergoline preparation method |
| 05/26/2006 | WO2006053884A1 Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
| 05/26/2006 | WO2006053860A1 Isoxazolic derivative to relieve neuropathic pain |
| 05/26/2006 | WO2006053785A1 Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality |
| 05/26/2006 | WO2006053780A1 Crystalline aripiprazole solvates |
| 05/26/2006 | WO2006053760A1 Pharmaceutical compositions comprising (+) - (2s, 3s) - 2 - (chlorophenyl) - 3, 5, 5-trimethhyl-2-morpholinol |
| 05/26/2006 | WO2006053428A1 Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation |
| 05/26/2006 | WO2006053390A1 A method of modulating b cell functioning |
| 05/26/2006 | WO2006053379A1 Improved nutraceutical composition |
| 05/26/2006 | WO2006031786A3 Protein a compositions and methods of use |
| 05/26/2006 | WO2006027052A3 (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators |
| 05/26/2006 | WO2006015590A3 Novel formulation for l-tryptophane comprising carbidopa/benserazide |
| 05/26/2006 | WO2005120542A3 Methods of treating disease with random copolymers |
| 05/26/2006 | WO2005120435A3 Method for preparing sustained release compositions and the use of said compositions for treating chronic diseases of central nervous system (cns) |
| 05/26/2006 | WO2005118634A3 Helical peptidomimetics with enhanced activity against beta-amyloid production |
| 05/26/2006 | WO2005115471A3 Methods and compositions for treatment of nicotine dependence and dementias |
| 05/26/2006 | WO2005108358A3 Pyrrolidine derivatives useful as bace inhibitors |
| 05/26/2006 | WO2005055993A3 Pharmaceutical preparation containing gabapentin |
| 05/26/2006 | WO2004084835A3 Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor |
| 05/26/2006 | CA2838516A1 Treatment of disease |
| 05/26/2006 | CA2588423A1 Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation |
| 05/26/2006 | CA2588381A1 Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality |
| 05/26/2006 | CA2587732A1 Glycogen synthase kinase-3 inhibitors |
| 05/26/2006 | CA2587598A1 Bis(thio-hydrazide amides) for increasing hsp70 expression |
| 05/26/2006 | CA2587407A1 A method of modulating b cell functioning |
| 05/26/2006 | CA2587398A1 Gpr7-selective ligand and use thereof |
| 05/26/2006 | CA2586365A1 Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders |
| 05/26/2006 | CA2586358A1 Use of tetrahydrocannabivarin (thcv) as neutral antagonist of the cb1 cannabinoid receptors |
| 05/26/2006 | CA2585359A1 Gaba-steroid antagonists and their use for the treatment of cns disorders |
| 05/26/2006 | CA2585317A1 Drug combination for the treatment of depression and related disorders comprising a selective serotonin reuptake inhibitor |
| 05/26/2006 | CA2584619A1 Amide compound |
| 05/25/2006 | US20060111567 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists |
| 05/25/2006 | US20060111556 Preventives/remedies for neurodegenerative diseases |
| 05/25/2006 | US20060111446 5-Amidino-N-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, pharmaceutical use thereof, and intermediate therefor |
| 05/25/2006 | US20060111424 Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione |
| 05/25/2006 | US20060111419 Novel fused indazole compounds |
| 05/25/2006 | US20060111418 Blood-brain barrier disruption inhibitor |
| 05/25/2006 | US20060111408 Therapeutic benzothiazole compounds |
| 05/25/2006 | US20060111400 Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
| 05/25/2006 | US20060111397 Methods and compositions for treating diseases associated with excesses in ACE |
| 05/25/2006 | US20060111390 Azaindoles as inhibitors of c-jun n-terminal kinases |
| 05/25/2006 | US20060111381 Amidine compounds |
| 05/25/2006 | US20060111373 Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists |
| 05/25/2006 | US20060111372 Alkyl-substituted pyrazolopyrimidines |
| 05/25/2006 | US20060111368 Phosphodiesterase inhibitor |
| 05/25/2006 | US20060111362 1,3-Dihydroimidazole ring compound |
| 05/25/2006 | US20060111359 enzyme inhibitor for treating sleep disorders |
| 05/25/2006 | US20060111344 Arylethanolamine beta2-adrenoreceptor agonist compounds |